The radiosynthesis of [(18) F]DCFPyL on 2 distinct automated platforms with full regulatory compliant quality control specifications is described. The radiotracer synthesis was performed on a custom-made radiofluorination module and the Sofie Biosciences ELIXYS. The radiofluorination module synthesis was accomplished in an average of 66 minutes from end of bombardment with an average specific activity at end of synthesis (EOS) of 4.4 TBq/μmol (120 Ci/μmol) and an average radiochemical yield of 30.9% at EOS. The ELIXYS synthesis was completed in an average of 87 minutes with an average specific activity of 2.2 TBq/μmol (59.3 Ci/μmol) and an average radiochemical yield of 19% at EOS. Both synthesis modules produced large millicurie quantities of [(18) F]DCFPyL while conforming to all standard US Pharmacopeia Chapter <823> acceptance testing criteria.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516894 | PMC |
| http://dx.doi.org/10.1002/jlcr.3430 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Normal-organ distribution of PSMA-targeting PET radiopharmaceutical F-flotufolastat: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies.
Am J Nucl Med Mol Imaging
October 2024
Blue Earth Diagnostics Ltd. The Oxford Science Park, Magdalen Centre, Robert Robinson Avenue, Oxford, OX4 4GA, UK.
Background: High-affinity radiohybrid PSMA-targeting radiopharmaceutical F-flotufolastat (F-rhPSMA-7.3) is newly approved for diagnostic imaging of prostate cancer. Here, we conduct a post hoc analysis of two phase 3 studies to quantify F-flotufolastat uptake in a range of normal organs.
View Article and Find Full Text PDFMediastinal lymph node metastases from prostate cancer: Enhanced diagnostic accuracy of PET/CT with F-DCFPyL versus F-choline.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
October 2024
Servicio de Medicina Nuclear, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
Clinical Factors Associated With Suspicious F-DCFPyL PSMA PET Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL.
J Urol
October 2024
Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
Purpose: There are limited data on PSMA PET/CT for workup of recurrence after radical prostatectomy (RP) at low PSA values. We evaluated a PSMA PET/CT cohort of patients with post-RP, focusing on patients with PSA < 0.5 ng/mL.
View Article and Find Full Text PDFPatterns of failure with F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting: A regional cohort analysis.
Can Urol Assoc J
October 2024
McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Introduction: This study aimed to assess the detection rate of prostate cancer recurrence by prostate-specific member antigen positron emission tomography/computed tomography (PSMA PET/CT) with F-DCFPyL in patients with residual disease or biochemical recurrence (BCR), and its association with surgical pathology and prostate-specific antigen (PSA) kinetics.
Methods: Men from South Central Ontario enrolled in the PSMA Registry for Recurrent Prostate cancer (PREP) between April 2019 and December 2021 after radical prostatectomy (RP) and who had 1) pathologic stage N1 or persistent elevated PSA; or 2) BCR (PSA >0.10 ng/mL) where initial postoperative PSA was undetectable were included.
Prostate-specific membrane antigen PET versus [Tc]Tc-MDP bone scan for diagnosing bone metastasis in prostate cancer: a head-to-head comparative meta-analysis.
Front Med (Lausanne)
September 2024
Department of Urology Surgery, First Hospital of Jilin University, Changchun, China.
Purpose: To evaluate the diagnostic performance of PSMA PET/CT, including [Ga]Ga-PSMA-11 and [F]DCFPyL, in comparison with the [Tc]Tc-MDP bone scan (BS) in identifying bone metastases among prostate cancer patients.
Methods: A search was performed in the PubMed and Embase databases to locate pertinent publications from inception to February 12, 2024. The studies included were those that examined the diagnostic effectiveness of PSMA PET/CT (covering [Ga]Ga-PSMA-11 and [F]DCFPyL) compared to [Tc]Tc-MDP BS in identifying bone metastases among prostate cancer patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!